| | |
| Clinical data | |
|---|---|
| Other names | (R)-Praziquantel |
| Drug class | Anthelmintic |
| ATC code | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| PDB ligand | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C19H24N2O2 |
| Molar mass | 312.413 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Arpraziquantel ((R)-praziquantel) is the eutomer (the biologically active enantiomer) of praziquantel, and is a medication which is currently under investigation for the treatment of schistosomiasis in young children since it has less side effects than the usual racemic mixture formulation of praziquantel. [1]
Arpraziquantel is a therapeutic alternative on the World Health Organization's List of Essential Medicines. [2]
In December 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion in accordance with Article 58 of Regulation (EC) No 726/20041 for the medicinal product arpraziquantel, intended for the treatment of schistosomiasis in young children. [1] The applicant for this medicinal product is Merck Europe B.V. [1] It is intended exclusively for markets outside the European Union. [1]
Arpraziquantel is the International nonproprietary name. [3]